ArticleAnatolian journal of cardiology2026
Electrophysiological Markers in Hypertrophic Cardiomyopathy: Enhancing Sudden Cardiac Death Risk Prediction with Index of Cardiac Electrophysiological Balance and Its Corrected Variant.
Article in Anatolian journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ferric Carboxymaltose Therapy Improves the Index of Cardiac Electrophysiological Balance in Iron-Deficient Heart Failure with Reduced Ejection Fraction.Medicina (Kaunas, Lithuania) · 2026Article
- Reply to the Letter to the Editor: "Integrated Clinical, Multimodality Imaging, and Electrophysiological Markers for Improved Prediction of Sudden Cardiac Death in Hypertrophic Cardiomyopathy".Anatolian journal of cardiology · 2026Article
- Exploring the Multifaceted Nexus of Hypertrophic Cardiomyopathy and Clinical Outcomes.Anatolian journal of cardiology · 2026Article
- Integrated Clinical, Multimodality Imaging, and Electrophysiological Markers for Improved Prediction of Sudden Cardiac Death in Hypertrophic Cardiomyopathy.Anatolian journal of cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is characterized by asymmetric left ventricular hypertrophy and myocardial fibrosis, which significantly increases the risk of sudden cardiac death (SCD). Existing risk stratification models are limited in predicting SCD risk in patients within the "gray zone"-those with intermediate risk. This study investigates the prognostic utility of the Index of Cardiac Electrophysiological Balance (ICEB) and its corrected variant (ICEBc) in predicting ventricular arrhythmias (VAs) in HCM. To evaluate the predictive value of ICEB and ICEBc for Life-Threatening Arrhythmias (LTA) and non-sustained ventricular tachycardia (NSVT) in HCM and compare their performance with traditional repolarization parameters and the European Society of Cardiology (ESC) SCD Risk Score.
methodsA retrospective observational study was conducted at a single center, including 127 HCM patients categorized into 3 groups: LTA (n = 45), NSVT (n = 29), and control (n = 53). Electrocardiographic parameters, including ICEB, ICEBc, Tp-e interval, Tp-e/QTc ratio, and QRS-T angle were measured. Multiple logistic regression and receiver operating characteristic (ROC) curve analyses were performed to identify independent predictors of VAs.
resultsThe ICEB and ICEBc were significantly lower in LTA and NSVT groups compared to the control group (P < .001), indicating increased arrhythmogenic risk. The ROC curve analysis showed that ICEB and ICEBc had superior predictive power for LTA and NSVT compared to traditional markers and the ESC SCD Risk Score, with the highest area under the curve (AUC) for the Base + ICEB Model (AUC = 0.79).
conclusionThe ICEB and ICEBc are robust markers of repolarization heterogeneity and effective predictors of VAs in HCM patients. Their integration into existing risk stratification models could enhance predictive accuracy, particularly for gray zone patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.